Atea Reports Positive Late-Stage Trial Results for Hepatitis C Drug
Atea Pharmaceuticals (AVIR) announced positive results from its late-stage trial of BEM/RZR, a treatment candidate for chronic hepatitis C. The Phase 3 C-BEYOND study showed topline data supporting the drug's efficacy and safety profile in treating this blood-borne liver infection. Despite these promising clinical outcomes, Atea’s stock traded lower on Tuesday following the announcement. This market reaction may reflect investor skepticism or broader sector dynamics rather than a direct response to the trial results themselves.
